Physician profile
Eric J Schwartz
NPI 1366446064
$4,919.28
in general payments reported to CMS, 2019-2025
39 companies · $519 in 2025
The $519 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $1,091 · 2021: $860 · 2022: $278 · 2023: $841 · 2024: $741 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085 · Gift: $16.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.67 |
| Gift | $16.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $976.11 | 2020 | |
| Procept Biorobotics Corporation | $525.74 | 2021 | |
| Urogen Pharma, INC. | $360.29 | 2020-2025 | Jelmyto |
| Dendreon Pharmaceuticals LLC | $337.21 | 2019-2025 | Provenge |
| Teleflex LLC | $311.16 | 2021-2025 | Urolift |
| Janssen Biotech, INC. | $245.32 | 2019-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $205.01 | 2019-2023 | Myrbetriq |
| Olympus America INC. | $163.79 | 2023-2025 | Itind System, Tecoflex |
| Allergan, INC. | $137.87 | 2019 | |
| Tolmar, INC. | $134.77 | 2023-2025 | Eligard, Jatenzo |
| Baxter Healthcare | $133.75 | 2019-2024 | Tisseel |
| Bayer Healthcare Pharmaceuticals INC. | $133.54 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $123.89 | 2023-2025 | Gemtesa, Orgovyx |
| Axonics, INC. | $123.53 | 2022-2024 | Axonics |
| Pfizer INC. | $111.17 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $93.93 | 2021-2022 | |
| Abbvie INC. | $82.77 | 2019-2024 | Lupron Depot |
| 180 Medical, INC. | $77.92 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $72.57 | 2024-2025 | Adstiladrin |
| Coloplast Corp | $67.66 | 2023 | Titan |
| Agiliti Surgical, INC. | $54.41 | 2023 | Sonablate |
| Telix Pharmaceuticals | $46.86 | 2024-2025 | Illuccix |
| Endo Pharmaceuticals INC. | $45.71 | 2019-2023 | Aveed, Xiaflex |
| Avadel Specialty Pharmaceuticals, LLC | $33.01 | 2019 | |
| Sagent Pharmaceuticals | $30.38 | 2023 | Glydo |
| Tempus Ai, INC | $29.35 | 2024 | Xt Cdx |
| Antares Pharma, INC. | $28.84 | 2024 | Xyosted, Tlando |
| Immunitybio, INC. | $24.42 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $23.57 | 2020 | |
| Merck Sharp & Dohme LLC | $21.99 | 2025 | Keytruda |
| Halozyme INC | $21.77 | 2023 | |
| Medtronic, INC. | $21.13 | 2022 | |
| Calyxo, INC. | $19.32 | 2025 | Cvac Aspiration System |
| Daiichi Sankyo INC. | $18.81 | 2020 | |
| Hollister Incorporated | $17.33 | 2023 | Vapro |
| Verity Pharmaceuticals INC. | $16.88 | 2025 | Trelstar |
| Accord Healthcare, INC. | $16.65 | 2024 | |
| Sun Pharmaceutical Industries INC. | $16.25 | 2019 | |
| Zyla Life Sciences, INC. | $14.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.